GSK, Theravance Announce Positive Phase IIb Results for Asthma Treatment

GlaxoSmithKline (GSK) and Theravance, Inc. announced positive results from three, separate phase 2b studies assessing efficacy and safety of GSK’s inhaled corticosteroid (ICS) fluticasone furoate (FF or GW685698) across a range of eight doses (25–800 mcg) in over 1,800 patients with mild, moderate and severe asthma.
CNN Money